Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study - Concepedia

Concepedia

Publication | Open Access

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

DOI Full Paper Access

29

Citations

39

References

2023

Year

Michela Casanova, Francisco Bautista, Quentin Campbell-Hewson, Guy Makin, Lynley V. Marshall, Arnauld Verschuur, Adela Cañete, Nadège Corradini, Bart A. Ploeger, Barbara J. Brennan,

Clinical Cancer Research

Abstract

Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (ClinicalTrials.gov NCT02085148).

References

	Year	Citations

Page 1